Sandoz

The Swiss stock market closed higher: the SMI rose 1.2% to 14,757 points and hit an intraday record at 14,862 points. The market was supported by the Fed and ECB decisions to keep key interest rates unchanged. Sandoz gained 4.4%, the biggest mover after a rebound from the previous day's losses; UBS rose 2.9% following positive analyst comments, Novartis gained 2.4%, and Logitech extended its prior-day losses. » Más en finanzen.net

Sandoz reported a revenue increase of 8% to USD 8.7 billion for the first nine months, driven by double-digit gains in the biosimilars business while generics suffered from price declines. For 2026, management now expects constant‑currency revenue growth of 5–6% instead of the previously forecast mid‑to‑high single‑digit range. The core EBITDA margin has been raised to 23.0–23.5% (prior year 21.7%), attributed to a more favorable revenue mix and stronger operational performance. The stock fell sharply as a result. » Más en finanzen.net

The Sandoz plant in Kundl is the last fully integrated penicillin factory in Europe, but it is threatened with closure because of significantly cheaper Chinese competition and high energy and production costs. Despite EU funding to expand capacity, production is economically unviable according to Sandoz, which has therefore filed an anti-dumping investigation in Brussels against Chinese active ingredients. Closing the facility would massively increase Europe’s dependence on China for vital antibiotics and endanger supply security. » Más en n-tv.de